Pune-based Emcure Pharmaceuticals has pulled out its proposed red herring prospectus or DRHP with securities market regulator SEBI. Emcure Pharmaceuticals on Wednesday said it has filed a draft red herring prospectus (DRHP) with the Sebi for launching an initial public offer. Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus ( DRHP) with SEBI for initial public offering that includes fresh issue.
|Published (Last):||7 March 2008|
|PDF File Size:||5.14 Mb|
|ePub File Size:||4.86 Mb|
|Price:||Free* [*Free Regsitration Required]|
We have not given a thought to a pre-IPO funding round. My Saved Articles Sign in Sign up. Infibeam calls off pact to acquire Snapdeal unit Unicommerce. British support-services provider Serco Group Plc.
Emcure operates nine manufacturing facilities, eight of which are located in India and one in the United States. Log in Keep me signed in. Find this comment offensive?
Here’s how the world is celebrating Christmas. Will the government be able to play The firm is now evaluating options for an offshore listing. Emcure is ranked as the 14th-largest pharmaceutical company in India in terms of market share based on the domestic sales of pharmaceutical products. Bain Capital has paid nearly Rs. Sensex finishes year above 36, posts third straight annual gain.
NIFTY 50 10, 2. Private equity major Blackstone has started the process of exiting its maiden investment in India, Emcure Pharmaceuticals.
Emcure Pharmaceuticals files IPO papers with SEBI –
In AprilEmcure acquired Heritage Pharmaceuticals, a New Jersey-based generic pharmaceutical company, which provided it a commercial platform to market and sell its products.
Your Reason has been Reported to the admin. It is ranked as the 7th-largest pharmaceutical company in the therapeutic areas in which it operates. Drnp miss a great news story! By Jasleen Kaur Batra. Technicals Technical Chart Visualize Screener. The pharma company intends to utilise the net proceeds for setting up of new manufacturing facilities and expansion of existing manufacturing facilities; research and development; and general corporate purposes.
Emcuee areas include cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals drh nutrients. Read more on Emcure Pharmaceuticals. It is ranked much higher in the therapeutic areas in which it operates.
The transaction is subject to conditions under contract and law including Foreign Investment Promotion Board approval. Promoter Satish Ramanlal Mehta holds Secondary transactions set the ground for appropriate ecmure as there is no information arbitrage unlike in a primary transaction. Of these revenues, Book running lead managers to the issue include Bank of America Merrill Lynch.
To see your saved stories, click on link hightlighted in bold. This will alert our moderators to take action Name Reason for reporting: This is the second exit by Blackstone from its India portfolio. Blackstone Emcure Bain Capital private equity stake. Blackstone has exited now. This follows a deal struck late last year where Blackstone sold its stake to Bain Capital for an undisclosed amount.
Emcure Pharmaceuticals files IPO papers with SEBI
Reliance to buy majority stake in renewable energy services firm Kanoda. Choose your reason below and click on the Report button. Get instant notifications from Economic Times Allow Not now You can switch off notifications anytime using browser settings. Edited by Joby Puthuparampil Johnson.